Pembrolizumab in mycosis fungoides with PD-L1 structural variants

•PD-L1 structural variants are recurrent in mycosis fungoides with large cell transformation.•PD-L1 structural variants in relapsed/refractory mycosis fungoides should prompt consideration of treatment with PD-1 inhibitors.

Saved in:
Bibliographic Details
Published in:Blood advances 2021-02, Vol.5 (3), p.771-774
Main Authors: Beygi, Sara, Fernandez-Pol, Sebastian, Duran, George, Wang, Erica B., Stehr, Henning, Zehnder, James L., Ramchurren, Nirasha, Fling, Steven P., Cheever, Martin A., Weng, Wen-Kai, Kim, Youn H., Khodadoust, Michael S.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - therapeutic use
B7-H1 Antigen
Humans
Mycosis Fungoides - drug therapy
Skin Neoplasms - drug therapy
Stimulus Report
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•PD-L1 structural variants are recurrent in mycosis fungoides with large cell transformation.•PD-L1 structural variants in relapsed/refractory mycosis fungoides should prompt consideration of treatment with PD-1 inhibitors.
ISSN:2473-9529
2473-9537
DOI:10.1182/bloodadvances.2020002371